1. Home
  2. APLM vs SONM Comparison

APLM vs SONM Comparison

Compare APLM & SONM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLM
  • SONM
  • Stock Information
  • Founded
  • APLM 2016
  • SONM 1999
  • Country
  • APLM United States
  • SONM United States
  • Employees
  • APLM N/A
  • SONM N/A
  • Industry
  • APLM Blank Checks
  • SONM Telecommunications Equipment
  • Sector
  • APLM Finance
  • SONM Telecommunications
  • Exchange
  • APLM Nasdaq
  • SONM Nasdaq
  • Market Cap
  • APLM 15.6M
  • SONM 15.0M
  • IPO Year
  • APLM N/A
  • SONM 2019
  • Fundamental
  • Price
  • APLM $0.16
  • SONM $2.80
  • Analyst Decision
  • APLM Strong Buy
  • SONM
  • Analyst Count
  • APLM 2
  • SONM 0
  • Target Price
  • APLM $4.25
  • SONM N/A
  • AVG Volume (30 Days)
  • APLM 1.0M
  • SONM 20.4K
  • Earning Date
  • APLM 08-14-2024
  • SONM 11-12-2024
  • Dividend Yield
  • APLM N/A
  • SONM N/A
  • EPS Growth
  • APLM N/A
  • SONM N/A
  • EPS
  • APLM N/A
  • SONM N/A
  • Revenue
  • APLM $2,101,000.00
  • SONM $69,288,000.00
  • Revenue This Year
  • APLM N/A
  • SONM N/A
  • Revenue Next Year
  • APLM N/A
  • SONM $107.78
  • P/E Ratio
  • APLM N/A
  • SONM N/A
  • Revenue Growth
  • APLM 70.54
  • SONM N/A
  • 52 Week Low
  • APLM $0.11
  • SONM $2.32
  • 52 Week High
  • APLM $3.20
  • SONM $10.70
  • Technical
  • Relative Strength Index (RSI)
  • APLM 66.49
  • SONM 48.96
  • Support Level
  • APLM $0.13
  • SONM $2.79
  • Resistance Level
  • APLM $0.18
  • SONM $3.11
  • Average True Range (ATR)
  • APLM 0.01
  • SONM 0.28
  • MACD
  • APLM 0.00
  • SONM 0.05
  • Stochastic Oscillator
  • APLM 79.31
  • SONM 23.91

About APLM Apollomics Inc.

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

About SONM Sonim Technologies Inc.

Sonim Technologies Inc is a provider of ultra-rugged mobile devices, including phones and accessories designed specifically for task workers physically engaged in their work environments, often in mission-critical roles. The company sells mobile phones, accessories, and solutions to AT&T, T-Mobile, and Verizon in the United States, and to Bell, Rogers, and Telus Mobility in Canada. The products include rugged mobile phones that can attach to both public and private wireless networks, industrial-grade accessories that meet the requirements of specific applications and software applications, and cloud-based tools that provide management and deployment services to customers. The company generates revenue from discounts, price protection, and customer incentives.

Share on Social Networks: